These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 24470552)

  • 21. Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors.
    Mahller YY; Vaikunth SS; Ripberger MC; Baird WH; Saeki Y; Cancelas JA; Crombleholme TM; Cripe TP
    Cancer Res; 2008 Feb; 68(4):1170-9. PubMed ID: 18281493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.
    Barnard Z; Wakimoto H; Zaupa C; Patel AP; Klehm J; Martuza RL; Rabkin SD; Curry WT
    Neurosurgery; 2012 Sep; 71(3):741-8; discussion 748. PubMed ID: 22653387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine.
    Castellsagué J; Gel B; Fernández-Rodríguez J; Llatjós R; Blanco I; Benavente Y; Pérez-Sidelnikova D; García-Del Muro J; Viñals JM; Vidal A; Valdés-Mas R; Terribas E; López-Doriga A; Pujana MA; Capellá G; Puente XS; Serra E; Villanueva A; Lázaro C
    EMBO Mol Med; 2015 May; 7(5):608-27. PubMed ID: 25810463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors.
    Paudel SN; Hutzen BJ; Miller KE; Garfinkle EAR; Chen CY; Wang PY; Glaspell AM; Currier MA; Ringwalt EM; Boon L; Mardis ER; Cairo MS; Ratner N; Dodd RD; Cassady KA; Cripe TP
    Front Immunol; 2024; 15():1384623. PubMed ID: 39044819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.
    Wakimoto H; Kesari S; Farrell CJ; Curry WT; Zaupa C; Aghi M; Kuroda T; Stemmer-Rachamimov A; Shah K; Liu TC; Jeyaretna DS; Debasitis J; Pruszak J; Martuza RL; Rabkin SD
    Cancer Res; 2009 Apr; 69(8):3472-81. PubMed ID: 19351838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta.
    Prabhakar S; Messerli SM; Stemmer-Rachamimov AO; Liu TC; Rabkin S; Martuza R; Breakefield XO
    Cancer Gene Ther; 2007 May; 14(5):460-7. PubMed ID: 17304235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced IL-12 transgene expression improves oncolytic viroimmunotherapy.
    Kim Y; Saini U; Kim D; Hernandez-Aguirre I; Hedberg J; Martin A; Mo X; Cripe TP; Markert J; Cassady KA; Dhital R
    Front Immunol; 2024; 15():1375413. PubMed ID: 38895115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines.
    Jackson JD; McMorris AM; Roth JC; Coleman JM; Whitley RJ; Gillespie GY; Carroll SL; Markert JM; Cassady KA
    Gene Ther; 2014 Nov; 21(11):984-90. PubMed ID: 25119379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.
    Fukuhara H; Martuza RL; Rabkin SD; Ito Y; Todo T
    Clin Cancer Res; 2005 Nov; 11(21):7886-90. PubMed ID: 16278413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
    Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
    Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of breast cancer stem cells with oncolytic herpes simplex virus.
    Li J; Zeng W; Huang Y; Zhang Q; Hu P; Rabkin SD; Liu R
    Cancer Gene Ther; 2012 Oct; 19(10):707-14. PubMed ID: 22898897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncolytic herpes virus G47Δ injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis.
    Uchihashi T; Nakahara H; Fukuhara H; Iwai M; Ito H; Sugauchi A; Tanaka M; Kogo M; Todo T
    Mol Ther Oncolytics; 2021 Sep; 22():388-398. PubMed ID: 34553027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
    Aghi M; Rabkin SD; Martuza RL
    Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells.
    Farrell CJ; Zaupa C; Barnard Z; Maley J; Martuza RL; Rabkin SD; Curry WT
    Clin Cancer Res; 2008 Dec; 14(23):7711-6. PubMed ID: 19047097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice.
    Liu R; Varghese S; Rabkin SD
    Cancer Res; 2005 Feb; 65(4):1532-40. PubMed ID: 15735042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain.
    Liu R; Martuza RL; Rabkin SD
    Gene Ther; 2005 Apr; 12(8):647-54. PubMed ID: 15647762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer.
    Zeng WG; Li JJ; Hu P; Lei L; Wang JN; Liu RB
    Oncol Rep; 2013 Jun; 29(6):2355-61. PubMed ID: 23525624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncolytic herpes simplex virus therapy for peripheral nerve tumors.
    Jeyaretna DS; Rabkin SD; Martuza RL
    Neurosurg Focus; 2007 Jun; 22(6):E4. PubMed ID: 17613221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of a third-generation oncolytic herpes virus G47Δ in models of human esophageal carcinoma.
    Yajima S; Sugawara K; Iwai M; Tanaka M; Seto Y; Todo T
    Mol Ther Oncolytics; 2021 Dec; 23():402-411. PubMed ID: 34853811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.
    Cheema TA; Wakimoto H; Fecci PE; Ning J; Kuroda T; Jeyaretna DS; Martuza RL; Rabkin SD
    Proc Natl Acad Sci U S A; 2013 Jul; 110(29):12006-11. PubMed ID: 23754388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.